(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from IQVIA Institute for Human Data Science, 2018 and Beyond: Outlook and Turning Points. Key findings from the report include: Rebates and discounts
(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s 100-day review of the actions needed to address vulnerabilities in our nation’s pharmaceutical supply chain and what measures need to be taken in order
The Pharmaceutical Care Management Association recently submitted a letter to the Council of Economic Advisers. Click here for the letter PCMA’s letter includes the following points: 1. The report offers no evidence to back its claim that the drug marketplace
PBMs leverage competition between drugs to create savings for patients.
Dr. Lawton Burns Says PBMs are Unfairly Blamed for High Drug Prices, Should Look At Big Drug Companies In case you missed it, Lawton R. Burns, PhD, professor of health care management at the Wharton School of the University of
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today is announcing a new three-part policy platform, supported by America’s pharmacy benefit managers, PBMs, aimed at reducing prescription drug costs by updating Medicare Part D, enhancing competition, and building toward a more value-driven
New Research Paper Demonstrates Declining Biosimilars Prices and Increasing Health Plan Coverage (Washington, D.C.) — Pharmacy benefit managers, PBMs, support the proliferation and use of biosimilars. A robust biosimilar market will increase competition for biologic drugs and provide added choice
(Washington, D.C.) — The number of independent pharmacies in the United States increased in 2020, according to a new analysis of pharmacy data. Pharmacy data from the National Council for Prescription Drug Programs, analyzed by the healthcare analytics firm Quest
(Washington, D.C.) — A new report, prepared by the research firm Milliman for the Pharmaceutical Care Management Association (PCMA), analyzed the financial impact of broad “Frozen Formulary” legislation in the fully insured commercial market on a nationwide basis. This study found
(Washington, D.C.) — A new report, prepared by the research firm Milliman, analyzed the financial impact of broad “Frozen Formulary” legislation in the fully insured commercial market on a nationwide basis. This study found that “Frozen Formulary” legislation could increase nationwide
©2024 PCMA. All Rights Reserved.
